Secondary syphilis occurring under anti-CD20 therapy: risks, progression and approach

An Bras Dermatol. 2024 Jul-Aug;99(4):632-634. doi: 10.1016/j.abd.2023.07.006. Epub 2024 Apr 12.

Authors

Luiz Augusto Fabricio de Melo Garbers¹, Tissiana Marques de Haes², Cacilda da Silva Souza³

Affiliations

¹ Department of Internal Medicine, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
² Department of Neurosciences and Behavioral Sciences, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
³ Department of Internal Medicine, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. Electronic address: [email protected].

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Disease Progression
Female
Humans
Male
Middle Aged
Risk Factors
Rituximab* / adverse effects
Rituximab* / therapeutic use
Syphilis* / drug therapy
Syphilis* / etiology

Substances

Rituximab

Supplementary concepts

Syphilis, secondary